Major medtech players Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) continue to support the use of their paclitaxel-eluting devices in the legs after a study released last month indicated a link between the devices and an increased mortality rate, according to a Star Tribune report.
In the meta-analysis, researchers led by Dr. Konstantinos Katsanos analyzed data from 28 trials involving paclitaxel-coated devices used in the femoral and/or popliteal artery. Data from the trial indicated a 68% relative increase in all-cause mortality risk with paclitaxel-coated devices after two years and a 93% relative increase after five years when compared to therapy with uncoated devices.
Results from the trial were published in the Journal of the American Heart Association in December.
Executives from both companies spoke at the J.P. Morgan Healthcare Conference in San Francisco suggesting that their own data does not support the higher death rates noted in the new study, according to the Star Tribune.
The post Report: Medtronic, Boston Scientific stand by paclitaxel-eluting devices despite JAHA study appeared first on MassDevice.